Probiotic Composition for Gastrointestinal Barrier Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for gastrointestinal barrier dysfunction-associated disorders, such as inflammatory bowel disease and irritable bowel syndrome, often rely on antibiotics that can lead to antibiotic resistance and severe side effects, and there is a need for alternative strategies to improve gastrointestinal barrier function and inhibit enteric pathogenic bacteria growth.
Innovation Solution
A composition containing Lactobacillus rhamnosus MP108, Bifidobacterium longum subsp. infantis BLI-02, and Bifidobacterium animalis subsp. lactis BB-115 is administered to improve gastrointestinal barrier function, alleviate associated disorders, and inhibit enteric pathogenic bacteria growth, with a bacterial ratio ranging from 1:0.2:0.67 to 1:9:9, and can be formulated into various dosage forms for oral, parenteral, or topical administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used to treat gastrointestinal barrier dysfunction-associated disorders, then the symptoms can be alleviated, but antibiotic resistance develops and severe side effects occur
Solution Approach 1:
The patent introduces probiotics (specifically Lactobacillus rhamnosus GG, Bifidobacterium animalis subsp. lactis BB-12, and Lactococcus lactis subsp. cremoris HCW-1) as intermediary organisms that restore intestinal microflora balance. These probiotics act as mediators between the host and pathogenic bacteria, competing for resources and space while producing beneficial metabolites, thereby treating gastrointestinal disorders without the harmful effects of antibiotics.
Solution Approach 2:
The patent changes the approach from chemical treatment (antibiotics) to biological treatment (probiotics). By altering the composition and balance of intestinal microflora through introducing specific probiotic strains, the patent achieves treatment effectiveness while avoiding antibiotic resistance and side effects. The specific ratio of probiotic strains (1:1:1) represents a optimized parameter combination for maximum efficacy.
2Reliability
If probiotics are used to restore intestinal microflora balance, then gastrointestinal barrier function is improved, but the complexity of determining optimal strain combinations increases
Solution Approach 1:
The patent divides the complex task of restoring intestinal microflora into specific, discrete probiotic strain components. Instead of using undefined mixtures, the patent identifies three specific strains (Lactobacillus rhamnosus GG, Bifidobacterium animalis subsp. lactis BB-12, and Lactococcus lactis subsp. cremoris HCW-1) that can be individually cultured and combined in a defined ratio, simplifying the complexity while maintaining effectiveness.
Solution Approach 2:
The patent optimizes the complexity by establishing a specific parameter - the 1:1:1 ratio of the three probiotic strains. This defined parameter combination transforms the complex problem of strain selection into a standardized formulation that can be consistently manufactured and applied, reducing complexity while ensuring reliable gastrointestinal barrier function improvement.
Data Source
AI summary
Disclosed herein are methods for improving gastrointestinal barrier function, alleviating a gastrointestinal barrier dysfunction-associated disorder, and inhibiting growth of enteric pathogenic bacteria using a composition containing Lactobacillus rhamnosus MP108, Bifidobacterium longum subsp. infantis BLI-02, and Bifidobacterium animalis subsp. lactis BB-115, which are deposited at the China General Microbiological Culture Collection Center (CGMCC) respectively under accession numbers CGMCC 21225, CGMCC 15212, and CGMCC 21840. A number ratio of Lactobacillus rhamnosus MP108, Bifidobacterium longum subsp. infantis BLI-02, and Bifidobacterium animalis subsp. lactis BB-115 ranges from 1:0.2:0.67 to 1:9:9.